ArticleInternational journal of hematology2022

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.

Hideki Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.